HC Wainwright Issues Positive Outlook for COLL Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Stock analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Collegium Pharmaceutical in a research report issued on Monday, March 24th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will post earnings per share of $1.75 for the quarter, up from their prior forecast of $1.61. HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million.

COLL has been the topic of a number of other reports. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.71 on Thursday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market cap of $935.45 million, a price-to-earnings ratio of 12.81 and a beta of 0.99. The stock’s 50-day moving average is $30.36 and its two-hundred day moving average is $32.45. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Collegium Pharmaceutical by 1.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after buying an additional 339 shares during the period. AlphaQuest LLC grew its holdings in shares of Collegium Pharmaceutical by 3.0% during the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after buying an additional 374 shares during the last quarter. Foundry Partners LLC increased its position in Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock valued at $463,000 after acquiring an additional 381 shares during the period. Finally, Gallacher Capital Management LLC raised its stake in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after acquiring an additional 470 shares during the last quarter.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares of the company’s stock, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.